GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » Gross Profit

CureVac NV (CureVac NV) Gross Profit : $-93.83 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Gross Profit?

CureVac NV's gross profit for the three months ended in Mar. 2024 was $-31.87 Mil. CureVac NV's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $-93.83 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. CureVac NV's gross profit for the three months ended in Mar. 2024 was $-31.87 Mil. CureVac NV's Revenue for the three months ended in Mar. 2024 was $13.45 Mil. Therefore, CureVac NV's Gross Margin % for the quarter that ended in Mar. 2024 was -236.93%.

CureVac NV had a gross margin of -236.93% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

During the past 6 years, the highest Gross Margin % of CureVac NV was 71.00%. The lowest was -172.91%. And the median was -95.98%.


CureVac NV Gross Profit Historical Data

The historical data trend for CureVac NV's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Gross Profit Chart

CureVac NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial -11.74 42.21 -152.77 -123.49 -77.00

CureVac NV Quarterly Data
Mar19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.46 -19.80 -8.32 -33.84 -31.87

Competitive Comparison of CureVac NV's Gross Profit

For the Biotechnology subindustry, CureVac NV's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CureVac NV's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's Gross Profit distribution charts can be found below:

* The bar in red indicates where CureVac NV's Gross Profit falls into.



CureVac NV Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

CureVac NV's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=58.624 - 135.623
=-77.00

CureVac NV's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=13.449 - 45.314
=-31.87

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-93.83 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

CureVac NV's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=-31.87 / 13.449
=-236.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


CureVac NV  (NAS:CVAC) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

CureVac NV had a gross margin of -236.93% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


CureVac NV Gross Profit Related Terms

Thank you for viewing the detailed overview of CureVac NV's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


CureVac NV (CureVac NV) Business Description

Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.